Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer
2015 IASLC World Conference on Lung Cancer
Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.
Vassiliki Papadimitrakopoulou, MD
Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerate research and access to care (Abstract MTE 02.01).
Alice T. Shaw, MD, PhD
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 33.03, 33.06, 33.07).
Guneet Walia, PhD
Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance therapy, and patient advocacy.
Nagashree Seetharamu, MD
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
Barbara J. Gitlitz, MD
Barbara J. Gitlitz, MD, of USC/Norris Cancer Center, discusses the first prospective study on the genomic drivers and demographics of lung cancer in patients under 40 who took part in the study remotely via the Internet (Abstract ORAL22.05).